866-997-4948(US-Canada Toll Free)

Cancer Genetics, Inc. (CGIX) - Product Pipeline Analysis, 2014 Update

Published By :

GlobalData

Published Date : Sep 2014

Category :

Cancer

No. of Pages : 36 Pages


Cancer Genetics, Inc. (CGI) is a pharmaceutical company. The company offers DNA-based cancer diagnostics products and services. Its products include DNA-FISH Probes, CGH Microarrays and Next-Generation Sequencing. CGIs oncology tests and laboratory services provide critical genomic information to healthcare professionals, biopharma companies, and cancer centers. The company provides clinical services such as test menu, complete program, expand DX and summation report. It collaborates with Cleveland Clinic, Dana Farber Cancer Institute, Georgia Health Sciences University, Hackensack University Medical Center, Kamineni Hospital, Mayo Clinic, Memorial Sloan-Kettering Cancer Center, and National Cancer Institute. CGI is headquartered in Rutherford, New Jersey, the US.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands. 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Cancer Genetics, Inc.
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents 

Table of Contents 2
List of Tables 4
List of Figures 4
Cancer Genetics, Inc. Company Snapshot 5
Cancer Genetics, Inc. Company Overview 5
Key Information 5
Cancer Genetics, Inc. Pipeline Products and Clinical Trials Overview 6
Cancer Genetics, Inc. Pipeline Analysis Overview 8
Key Facts 8
Cancer Genetics, Inc. - Major Products and Services 9
Cancer Genetics, Inc. Pipeline Products by Development Stage 10
Cancer Genetics, Inc. Pipeline Products Overview 12
FHACT Test - Head and Neck Cancer 12
FHACT Test - Head and Neck Cancer Product Overview 12
FReCaD Renal Cancer Test 13
FReCaD Renal Cancer Test Product Overview 13
LeukA - Leukemia 14
LeukA - Leukemia Product Overview 14
MatBA Diagnostic Test - Follicular Lymphoma 15
MatBA Diagnostic Test - Follicular Lymphoma Product Overview 15
MatBA Diagnostic Test - Multiple Myeloma 16
MatBA Diagnostic Test - Multiple Myeloma Product Overview 16
Next-Gen DNA Sequencing Assay - Hematological Cancer 17
Next-Gen DNA Sequencing Assay - Hematological Cancer Product Overview 17
Next-Gen DNA Sequencing Assay - Prostate Cancer 18
Next-Gen DNA Sequencing Assay - Prostate Cancer Product Overview 18
UGenRA - Cervix 19
UGenRA - Cervix Product Overview 19
UGenRA - Endometrium 20
UGenRA - Endometrium Product Overview 20
UGenRA - Ovary 21
UGenRA - Ovary Product Overview 21
UroGenRA - Bladder 22
UroGenRA - Bladder Product Overview 22
UroGenRA - Prostate 23
UroGenRA - Prostate Product Overview 23
Cancer Genetics, Inc. - Key Competitors 24
Cancer Genetics, Inc. - Key Employees 25
Cancer Genetics, Inc. - Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Cancer Genetics, Inc., Recent Developments 27
Sep 02, 2014: Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT, Receives CE Mark 27
Aug 27, 2014: Cancer Genetics' Proprietary Genomic Diagnostic Tests Added to National Institutes of Health's Genetic Testing Registry 27
Aug 25, 2014: Cancer Genetics and Leading Pathologist From Keck Medicine of USC Collaborate to Evaluate and Optimize Genomic Panel for Lymphoma 28
Aug 14, 2014: Cancer Genetics Reports Second Quarter 2014 Financial Results 28
Aug 04, 2014: Cancer Genetics Releases the Only Comprehensive Genomic Test to Diagnose & Stratify the Most Common Form of Leukemia (CLL) 31
Jun 03, 2014: Cancer Genetics, Inc. Partners With Leading Southwest Gynecological Pathology Lab to Provide Great Availability of FHACT, a Non-Invasive, Genomic Test to Guide the Detection and Management of Cervical Cancer 31
Apr 25, 2014: Cancer Genetics to Promote FHACT Test for Cervical Cancer at American Congress of Obstetricians and Gynecologists' Annual Clinical Meeting 32
Apr 04, 2014: Cancer Genetics Announces Launch of CALR Mutation Analysis Test to Assist in Diagnosis of Acute Leukemias & Myeloproliferative Neoplasms 33
Apr 03, 2014: Cancer Genetics to Present New Data From Renal Cell Carcinoma Study at AACR 34
Mar 26, 2014: Cancer Genetics Announces Fourth Quarter and Year-End 2013 Results, Provides Corporate Update 34

Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Table


Cancer Genetics, Inc., Key Facts 5
Cancer Genetics, Inc. Pipeline Products and Clinical Trials Overview 6
Cancer Genetics, Inc. Pipeline Products by Equipment Type 6
Cancer Genetics, Inc. Pipeline Products by Indication 7
Cancer Genetics, Inc., Key Facts 8
Cancer Genetics, Inc., Major Products and Services 9
Cancer Genetics, Inc. Number of Pipeline Products by Development Stage 10
Cancer Genetics, Inc. Pipeline Products Summary by Development Stage 11
FHACT Test - Head and Neck Cancer - Product Status 12
FHACT Test - Head and Neck Cancer - Product Description 12
FReCaD Renal Cancer Test - Product Status 13
FReCaD Renal Cancer Test - Product Description 13
LeukA - Leukemia - Product Status 14
LeukA - Leukemia - Product Description 14
MatBA Diagnostic Test - Follicular Lymphoma - Product Status 15
MatBA Diagnostic Test - Follicular Lymphoma - Product Description 15
MatBA Diagnostic Test - Multiple Myeloma - Product Status 16
MatBA Diagnostic Test - Multiple Myeloma - Product Description 16
Next-Gen DNA Sequencing Assay - Hematological Cancer - Product Status 17
Next-Gen DNA Sequencing Assay - Hematological Cancer - Product Description 17
Next-Gen DNA Sequencing Assay - Prostate Cancer - Product Status 18
Next-Gen DNA Sequencing Assay - Prostate Cancer - Product Description 18
UGenRA - Cervix - Product Status 19
UGenRA - Cervix - Product Description 19
UGenRA - Endometrium - Product Status 20
UGenRA - Endometrium - Product Description 20
UGenRA - Ovary - Product Status 21
UGenRA - Ovary - Product Description 21
UroGenRA - Bladder - Product Status 22
UroGenRA - Bladder - Product Description 22
UroGenRA - Prostate - Product Status 23
UroGenRA - Prostate - Product Description 23
Cancer Genetics, Inc., Key Employees 25
Cancer Genetics, Inc., Subsidiaries 26

List of Chart


Cancer Genetics, Inc. Pipeline Products by Equipment Type 7
Cancer Genetics, Inc. Pipeline Products by Development Stage 10

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *